Evotec SE Responds to Interest from Halozyme

Evotec SE has commented on a media report regarding a potential takeover. The company disclosed receiving a non-binding expression of interest from Halozyme Therapeutics Inc., a US biotechnology firm. The proposed offer suggests a price of EUR 11.00 per share for Evotec shareholders.

Evotec, based in Hamburg and traded on the Frankfurt Stock Exchange and NASDAQ, will analyze the offer carefully. The company is committed to keeping the market informed in compliance with legal standards.

This announcement comes amidst a regulatory disclosure by EQS News, detailing Evotec's position following Halozyme's unexpected approach. The firm's management, led by EVP Volker Braun, focuses on evaluating the next steps regarding this potential acquisition.